No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
002727 Yixintang Pharmaceutical
- 13.18
- -0.09-0.68%
Not Open Jul 24 15:00 CST
7.86BMarket Cap14.23P/E (TTM)
13.33High12.95Low83.44KlotVolume13.26Open13.27Pre Close109.88MTurnover2.05%Turnover Ratio14.30P/E (Static)596.01MShares26.5652wk High1.01P/B5.37BFloat Cap12.9552wk Low14.60Limit Up407.71MShs Float48.70Historical High11.94Limit Down2.86%Amplitude4.27Historical Low0.40Dividend TTM13.17Avg Price40.77KlotAsk3.03%Div YieldTTM100Lot Size40.01KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Yixintang pharmaceutical (002727.SZ): First repurchase of 2.0612 million shares, involving 27.2254 million yuan.
Yixintang pharmaceutical (002727.SZ) announced on July 24th that on July 24th, 2024, the company bought back 2.0612 million shares of company stock through a share repurchase special securities account using centralized bidding trading method, accounting for 0.35% of the total current share capital. The highest fill price was 13.33 yuan/share, the lowest fill price was 12.97 yuan/share, and the total amount of the trade was 27.2254 million yuan (excluding transaction fees).
Calculating The Intrinsic Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)
Yixintang Pharmaceutical: 2024 Interim Performance Forecast
Does Yixintang Pharmaceutical Group (SZSE:002727) Have A Healthy Balance Sheet?
Visiting yixintang pharmaceutical in person: unraveling the capital operation behind the thousands of stores.
A dual challenge of business and capital. Cai Jun from Investor Web recently reported that Yixintang Pharmaceutical (002727.sz, hereinafter referred to as the "Company") is facing a busy summer. In June, the company was talked to by the National Medical Insurance Bureau and, based on past regulatory issues, some stores have engaged in illegal use of medical insurance funds. In response, the company conducted its own self-inspection and will submit a rectification report to the National Medical Insurance Bureau at the end of the month. Subsequently, Yixintang disclosed multiple new measures such as share buybacks, acquisitions of more than 80 pharmacies and related inventories. From standing on the edge of the storm to frequent announcements, outsiders have raised doubts while the company is speaking out. Returning to the basics of business and capital.
Yixintang Pharmaceutical Unit Buys 29 Drug Stores for 16 Million Yuan
Comments
Yixintang Pharmaceutical Group's falling share price contrasts with its EPS growth and revenue increase, hinting at past over-hype and disappointing growth. Its poor performance over the past five years suggests potential issues, yet contrarian investors may see a turnaround opportunity.
4.8% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Yixintang Pharmaceutical Group (SZSE:002727) Shareholders Over That PeriodYixintang Pharmaceutical Group has demonstrated its ability to consistently reinvest at respectable rates of return. The market is beginning to recognize these trends, which could make this stock worth further investigation for potential investors.
1
Yixintang Pharmaceutical Group's low P/E ratio points to shareholder uncertainty about the future. This negative outlook could continue to pressure the company's shares and raise investment risks.
Yixintang Pharmaceutical Group's commendable performance is attributed to high return reinvestment, markedly increasing earnings. With predicted future robust ROE of 15% and growth rate, the company's successful investment strategy suggests a bright future.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg